The new entity will be listed on the New York Stock Exchange and is expected to generate pro forma revenue of $3.6 billion in ...

Dublin-headquartered Mallinckrodt is taking over smaller rival Endo and planning to list the combined firm on the New York Stock Exchange, the two drugmakers said Thursday.

Endo (NDOI) stock gains as the company is in pact with Mallinckrodt (MNKTQ) to merge in a $6.7B deal, creating a Dublin-based pharma leader. Read more here.

Mallinckrodt Pharmaceuticals and Endo Inc. plan to merge and create a $6.7 billion company in a move that will cut costs and broaden access to patients and new treatments.

(Reuters) - Mallinckrodt and Endo, drugmakers with a shared history of facing U.S. opioid litigation, have agreed to merge in ...

Despite strong financials and growth potential, Onto's stock appears fully valued, closely aligning with intrinsic value ...

Ready Capital Corporation (NYSE: RC) ("Ready Capital” or the "Company”) today announced that it has completed the previously announced acquisition of United Development Funding IV ("UDF IV”) (the ...

The merger will give the combined entity the financial flexibility to pursue drug licensing deals and broaden its therapeutic ...

Jeffs’ Brands Ltd. ( ($JFBR) ) just unveiled an update. On March 13, 2025, Jeffs’ Brands Ltd announced a significant milestone in the proposed ...

IAC Inc. (NASDAQ: IAC, $43.94, Market Cap: $3.6 billion) announced the record and distribution date for the planned spin-off ...

Mallinckrodt and Endo, drugmakers which recently emerged from bankruptcy after a wave of U.S. opioid lawsuits, announced ...

NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- Portman Ridge Finance Corporation (Nasdaq: PTMN) (the "Company” or "Portman Ridge”) announced today its financial results for the fourth quarter and full ...